Abstract: Objective To evaluate the clinical efficacy and safety of vinorelbine combined with nedaplatin for patients with cisplatinresistant advanced oral and maxillofacial cancer. Methods From Aug 2012 to Jul 2015, 42 advanced oral and maxillofacial cancer patients failed to the firstline cisplatinbased chemotherapy were treated with vinorelbine plus nedaplatin regimen. The regimen was taken as follow：vinorelbine 25 mg／m2 iv，d1，d 8；nedaplatin 80 mg／m2 iv，d1，d2，21 days as 1 cycle. The efficacy and adverse effects were respectively evaluated by RECIST guideline（version 1.1）and NCI CTC 4.0 criteria. Results All patients were available for evaluation，the overall response rate was 45.2％，the disease control rate was 73.8％，the median overall survival was 13 months（95％CI：10.91-15.09 months），and the median progress free survival was 7 months（95％CI：6.06-7.94 months）. The common adverse effects were myelosuppression and nausea/vomitting, maily in grade 1-2. Conclusion Combination of vinorelbine and nedaplatin for patients with cisplatin-resistant advanced oral and maxillofacial cancer is effective and well-tolerated，and is deserved further clinical research.